Literature DB >> 10942223

Management of patients with chronic, refractory idiopathic thrombocytopenic purpura.

J N George1, K Kojouri, J J Perdue, S K Vesely.   

Abstract

Chronic refractory idiopathic thrombocytopenic purpura (ITP) is defined as ITP with persistent thrombocytopenia despite conventional initial management with prednisone and splenectomy. Rare in children, It may occur in as many as one third of adults with ITP. The goal of treatment is not cure of the ITP, but only to achieve a safe platelet count, which is arbitrarily assumed to be greater than 30,000 to 50,000/microL. The risk for major bleeding seems great only when the platelet count is less than 10,000/microL. Treatment of patients with moderate thrombocytopenia and no clinically important bleeding symptoms should be avoided. There is no accepted algorithm for management of patients with chronic refractory ITP. Observation without specific treatment must be considered a cornerstone of management. Combination regimens of Immunosuppressive agents may be required for patients with severe and symptomatic thrombocytopenia. Additional supportive care measures are also important.

Entities:  

Mesh:

Year:  2000        PMID: 10942223     DOI: 10.1016/s0037-1963(00)90107-0

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  9 in total

Review 1.  Immune thrombocytopenia: no longer 'idiopathic'.

Authors:  Keith McCrae
Journal:  Cleve Clin J Med       Date:  2011-06       Impact factor: 2.321

2.  Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.

Authors:  Kiarash Kojouri; James N George
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 3.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

4.  Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.

Authors:  Motohiro Kato; Katsuyoshi Koh; Akira Kikuchi; Ryoji Hanada
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

Review 5.  Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.

Authors:  Oriana Miltiadous; Ming Hou; James B Bussel
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

6.  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Satoshi Hashino; Toshiro Nagasawa; Yoshiyuki Kurata; Yuji Kishimoto; Koji Iwato; Tomoko Ohtsu; Dietmar P Berger
Journal:  Int J Hematol       Date:  2009-06-20       Impact factor: 2.490

7.  Immune thrombocytopenic purpura caused by the over-the-counter weight supplement Root of Tejocote (Crataegus species).

Authors:  Hussam Alhasson; Eugene Muchnik
Journal:  Clin Case Rep       Date:  2020-03-20

8.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13

9.  High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

Authors:  Chae Young Kim; Eun Hye Lee; Hoi Soo Yoon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.